Gene therapy for hemoglobinopathies: are we there yet?
Puthenveetil G, Malik P.
Children's Hospital Los Angeles, Mail Stop 54,
4650 Sunset Boulevard,
Los Angeles, CA 90027, USA.
Curr Hematol Rep. 2004 Jul;3(4):298-305.
ABSTRACTBeta-Thalassemia and sickle cell disease constitute the most common single gene defect in humans and are characterized by absent/reduced and abnormal beta-globin, respectively. Patients with these hemoglobinopathies require chronic blood transfusions and rely on bone marrow transplant for a potential cure. Gene therapy provides a viable alternative by permanent correction of the defect in hematopoietic stem cells, but it has suffered from problems of vector instability, low viral titers, and variable expression of globin genes for more than a decade. This paper reviews the field of gene therapy for hemoglobinopathies with emphasis on the complexities of the beta-globin gene and its regulation, obstacles that have impeded progress, and recent advances in vector technology that will take this field forward toward the goal of successful genetic correction of these devastating diseases.Eugenics
'Liberal eugenics' (PDF)
Germline genetic engineering
Congenital insensitivity to pain
Artificial insemination and eugenics
Gene therapy and performance enhancement
An overview of Autism and Asperger syndrome
Transhumanism (H+): toward a Brave New World?
Preimplantation genetic diagnosis of haemophilia
and further reading
The Good Drug Guide
The Abolitionist Project
The Hedonistic Imperative
The Reproductive Revolution
MDMA: Utopian Pharmacology
Critique of Huxley's Brave New World